DALLAS--(BUSINESS WIRE)--Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced ...
iXCells’ mission is to empower life science researchers and patient foundations to advance personalized therapies and accelerate discovery of better medicines for a healthier future. iXCells’ cell ...
Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...
Century Therapeutics, Inc. announced it will present at the ASGCT 28th Annual Meeting, taking place from May 13-17, 2025, in New Orleans. The company will showcase data related to its preclinical cell ...
Cells can be reprogrammed, edited and differentiated into a wide variety of iPSC-derived cell types and 3-dimensional human cell models. iPSCore ™ incorporates extensive characterization, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback